Figure 3.

The use of monoclonal antibody therapy for preventing binding of SARS-CoV-2 to the ACE2 receptor as potential treatment of SARS-CoV-2. (a) Schematic representation for the neutralization mechanism of SARS-CoV-2. The SARS-CoV-2 spike protein-targeting monoclonal antibodies may limit the ability of the virus to attach to its cellular receptor, thereby preventing the virus from entering the cell. (b) SARS-CoV-targeting neutralizing monoclonal antibodies and their mode of action. These spike protein-targeting monoclonal antibodies showed promising results both in vitro and in vivo and could be potentially effective in combating SARS-CoV-2. (Adapted and modified with permission from Shanmugaraj et al.⁷⁵).